Methods for treating hematological disorders with VWF-targeting monospecific antibodies - Patents.com

Abstract

Provided herein are von Willebrand factor-binding antibodies directed to epitopes located in the cysteine ​​knot (CK) domain, which are useful in methods of treatment, such as methods of treating one or more blood disorders characterized by excessive bleeding.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 268,040, filed February 15, 2022, and U.S. Provisional Patent Application No. 63 / 269,000, filed March 8, 2022, the entire contents of which are incorporated herein by reference.

[0002] Sequence Listing This application has been submitted electronically in XML format and is accompanied by a Sequence Listing, which is incorporated herein by reference in its entirety. A copy of this XML was created on February 7, 2023, is named "HMT_002WO_Sequence Listing.xml", and is 457,851 bytes in size. Summary of the Invention

[0003] In certain embodiments, disclosed herein are compositions and methods for treating hematological disorders using monospecific antibodies targeted against von Willebrand factor (VWF).

[0004] In certain embodiments, disclosed herein are monospecific antibodies comprising an antigen-binding site that specifically binds to an epitope of von Willebrand factor (VWF) protein located in a cysteine ​​knot (CK) domain and a fragment crystallizable (Fc) region, wherein binding of the monospecific antibody disclosed herein to VWF protein results in accumulation of VWF protein in plasma compared to the plasma level of VWF protein in the absence of the monospecific antibody. In some embodiments, the antibodies disclosed herein are monovalent antibodies. In some embodiments, the Fc region is a wild-type Fc region. In some embodiments, the Fc region is a modified Fc region. In some embodiments, the modified Fc region comprises an R435H mutation, an N434A mutation, a T252L / T253S / T254F mutation, an E294delta / T307P / N434Y mutation, a T256N / A378V / S383N / N434Y mutation, an E294delta mutation, an M252Y / S254T / T256E mutation, an M428L / N434S mutation, a T307A / E380A / N434A mutation, an T250Q / M4 28L mutation, T250Q / M428F mutation, T250E / M428F mutation, T250E / M428L mutation, T256D / Q311V / A378V mutation, T256D / H286D / T307R / Q311V / A378V mutation, H285N / T307Q / N315D mutation, T307Q / Q311V / A378V mutation, H285D / T307Q / A378V mutation, L234F / L235E / P33 1S mutation, L234F / L235Q / K322Q mutation, L234F / L235Q / P331G mutation, L234F / L235A / K322Q mutation, S228P / F234A / L235A / G237A / P238S mutation, L234A / L235E / G237A / A330S / P331S mutation, F243A / V264A mutation, S228P / L235E / P329G mutation, M252Y / M428L mutations, D259I / V308F mutation, T307Q / N434S mutation, M428L / V308F mutation, Q311V / N434S mutation, H433K / N434F mutation, E258F / V427T mutation, K288E / H435K mutation, F234A / L235A mutation, F234A / L235A / S228P mutation, L234A / L235A / P329G mutation, F234A / L235A / P329G mutation,P329G mutation, F234 mutation, S228P mutation, delta-K447 mutation, L235A mutation, L235E mutation, V308P mutation, V308W mutation, V308Y mutation, V308F mutation, N434S mutation, T307 mutation, Q312A mutation, K322A mutation, P329A mutation, P331A mutation, P238A mutation, D265A mutation, D269A mutation, D270A mutation, N297A mutation, A32 The gene includes one or more mutations selected from the group consisting of a 7Q mutation, a P329A mutation, a S239A mutation, an E294A mutation, a Q295A mutation, a V303A mutation, an A330R mutation, a T299A mutation, a F234A mutation, a T366W mutation, a T366S mutation, a L368A mutation, a Y407V mutation, a F405L mutation, a K409R mutation, a F405L / R409K mutation, and any combination thereof. In some embodiments, the Fc region comprises an N-terminal truncation (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 20, 21, 2 In some embodiments, the antibody comprises a truncation by 2, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more N-terminal residues). In some embodiments, the antibody is a human IgG4 antibody comprising a first heavy chain and a second heavy chain. In some embodiments, the first heavy chain comprises S228P / T366W / F234A / L235A / delta-K447 mutations and the second heavy chain comprises S228P / T366S / L368A / Y407V / F234A / L235A / delta-K447 mutations. In some embodiments, the first heavy chain comprises S228P / T366W / delta-K447 mutations and the second heavy chain comprises S228P / T366S / L368A / Y407V / delta-K447 mutations. In some embodiments, the first heavy chain and the second heavy chain further comprise M252Y / S254T / T256E mutations. In some embodiments, the antibody comprises:and a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 16. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 16. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 16. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 16.The antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 12, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 13, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 14, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 15, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 18. In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 12, and a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 13, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 14, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 15. H3, and a variable heavy chain (VH) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 16, and comprising a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 17, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 18.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 453, and a variable light chain (VL) region at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 473. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 463; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 463. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 23. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 23. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 23.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 23. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 19, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:23. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 22, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 24, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 25.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 19, and a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 20, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 21, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 22. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 23 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 24, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 25.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 454, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 474. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 464; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 464. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO:26, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO:30. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 30. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 30.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 30. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 26, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 30. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 29, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 31, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ESS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 32.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 26, and a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 27, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 28, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 29. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 30 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 31, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 32, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 32. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 37. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 37. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 37.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 37. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 33, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 34, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 35, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 36, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 38, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of the DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 39.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 33, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 34, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 35, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 36. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 37 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 38, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 39, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 39.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 455, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 475. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 465; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 465. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 44. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 44. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 44.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 44. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 40, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 44. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 41, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 42, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 43, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 45, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GSS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 46.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 40, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 41, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 42, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 43. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 44, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 45, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: GSS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 46.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 456, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 476. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 466; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 466. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 51. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 51. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 51.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 51. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 47, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 51. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 48, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 49, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 50, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 52, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of the DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 53.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 47, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 48, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 49, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 50. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:51 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:52, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:53. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 58. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 58. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 58.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 58. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 54, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 58. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 55, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 56, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 57, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 59, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 60.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 54, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 55, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 56, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 57. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:58 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:59, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:60.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:457, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:477. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 467; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 467. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 65. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 65. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 65.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 65. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 61, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 65. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 67.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 61, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 62, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 63, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 64. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:65 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:66, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:67. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 72. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 72. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 72.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 72. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 68, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 72. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 71, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 73, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 74.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 68, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 69, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 70, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 71. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:72 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:73, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:74. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 79. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 79. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 79.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 79. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 75, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 79. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 78, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 80, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 81.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 75, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 76, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 77, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 78. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:79, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:80, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of HAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:81. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 86. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 86. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 86.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 86. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 82, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:86. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 83, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 84, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 85, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 87, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of the DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 88.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 82, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 83, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 84, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 85. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 86 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 87, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 88. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO:93. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 93. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 93.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 93. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 89, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:93. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 92, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 94, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 95.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 89, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 90, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 91, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 92. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:93, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:94, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:95.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:458, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO:478. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 468; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 468. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 100. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 100. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 100.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 100. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 96, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 100. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 97, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 98, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 99, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 101, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 102.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 96, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 97, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 98, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 99. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 100 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 101, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 102. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 103, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 107. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 103, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 107. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 103, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 107.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 103, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 107. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 103, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 107. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 104, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 106, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 108, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 109.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 103, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 104, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 105, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 106. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 107 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 108, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DIS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 109. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 110, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 114. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 110, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 114. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 110, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 114.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 110, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 114. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 110, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 114. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 113, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 115, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 116.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 110, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 111, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 112, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 113. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 114, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 115, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 116.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 459, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 479. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 469; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 469. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 121. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 121. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 121.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 121. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 117, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 121. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 120, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 122, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 123.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 117, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 118, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 119, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 120. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 121 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 122, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 123. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 128. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 128. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 128.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 128. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 124, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 128. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 127, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 129, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of EAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 130.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 124, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 125, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 126, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 127. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 128 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 129, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of EAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 130. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 135. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 135. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 135.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 135. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 131, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 135. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 134, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 136, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 137.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 131, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 132, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 133, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 134. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 135 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 136, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 137. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 138, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 142. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 138, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 142. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 138, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 142.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 138, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 142. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 138, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 142. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 141, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 143, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 144.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 138, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 139, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 140, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 141. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 142, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 143, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 144. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 145, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 149. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 145, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 149. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 145, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 149.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 145, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 149. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 145, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 149. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 148, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 150, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 151.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 145, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 146, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 147, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 148. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 149 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 150, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 151. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 152, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 156. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 152, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 156. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 152, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 156.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 152, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 156. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 152, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 156. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 155, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 157, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 158.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 152, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 153, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 154, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 155. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 156 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 157, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 158. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 159, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 163. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 159, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 163. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 159, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 163.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 159, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 163. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 159, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 163. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 162, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 164, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 165.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 159, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 160, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 161, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 162. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 163 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 164, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 165. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 166, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 170. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 166, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 170. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 166, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 170.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 166, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 170. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 166, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 170. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 169, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 171, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 172.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 166, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 167, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 168, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 169. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 170, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 171, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 172. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 173, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 177. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 173, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 177. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 173, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 177.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 173, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 177. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 173, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 177. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 176, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 178, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 179.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 173, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 174, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 175, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 176. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 177 and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 178, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 179. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 180, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 184. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 180, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 184. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 180, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 184.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 180, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 184. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 180, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 184. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 183, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 185, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DVS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 186.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 180, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 181, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 182, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 183. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 184 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 185, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DVS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 186. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 187, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 191. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 187, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 191. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 187, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 191.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 187, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 191. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 187, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 191. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 190, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 192, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of the DAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 193.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 187, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 188, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 189, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 190. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 86 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 191%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 192, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 192, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 193. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 194, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 198. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 194, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 198. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 194, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 198.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 194, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 198. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 194, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 198. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 197, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 199, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 200.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 194, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 195, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 196, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 197. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 198 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 199, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 200. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 201, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 205. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 201, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 205. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 201, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 205.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 201, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 205. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 201, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 205. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 204, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 206, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GVD, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 207.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 201, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 202, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 203, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 204. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 205, and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 206, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GVD, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 207. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 208, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 212. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 208, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 212. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 208, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 212.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 208, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 212. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 208, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 212. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 211, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 213, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 214.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 208, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 209, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 210, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 211. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 212, and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 213, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 214. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 215, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 219. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 215, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 219. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 215, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 219.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 215, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 219. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 215, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 219. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 218, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 220, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 221.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 215, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 216, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 217, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 218. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 219, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 220, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 221. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 222, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 226. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 222, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 226. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 222, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 226.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 222, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 226. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 222, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 226. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 225, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 227, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 228.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 222, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 223, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 224, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 225. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:226 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:227, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:228. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 229, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 233. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 229, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 233. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 229, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 233.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 229, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 233. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 229, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 233. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 232, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 234, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 235.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 229, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 230, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 231, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 232. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:233 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:234, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:235. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 236, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 240. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 236, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 240. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 236, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 240.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 236, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 240. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 236, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 240. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 239, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 241, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 242.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 236, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 237, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 238, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 239. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 240, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 241, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 242. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 243, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 247. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 243, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 247. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 243, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 247.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 243, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 247. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 243, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 247. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 244, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 245, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 246, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 248, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 249.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 243, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 244, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 245, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 246. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 247, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 248, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 249.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 460, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 480. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 470; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 470. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 250, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 254. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 250, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 254. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 250, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 254.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 250, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 254. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 250, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 254. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 251, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 252, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 253, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 255, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 256.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 250, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 251, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 252, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 253. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 254, and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 255, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAT, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 256. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 257, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 261. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 257, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 261. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 257, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 261.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 257, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 261. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 257, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 261. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 260, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 263.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 257, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 258, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 259, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 260. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 261, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 262, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 263. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 264, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 268. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 264, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 268. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 264, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 268.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 264, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 268. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 264, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 268. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 267, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 269, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAV, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 270.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 264, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 265, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 266, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 267. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:268 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:269, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAV, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:270. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 271, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 275. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 271, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 275. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 271, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 275.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 271, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 275. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 271, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 275. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 274, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 276, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 277.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 271, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 272, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 273, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 274. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 275, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 276, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 277. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 278, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 282. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 278, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 282. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 278, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 282.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 278, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 282. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 278, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 282. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 281, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 283, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 284.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 278, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 279, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 280, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 281. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 282, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 283, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 284. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 285, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 289. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 285, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 289. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 285, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 289.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 285, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 289. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 285, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 289. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 286, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 287, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 288, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 290, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 291.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 285, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 286, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 287, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 288. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 289, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 290, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 291. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 292, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 296. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 292, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 296. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 292, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 296.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 292, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 296. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 292, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 296. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 293, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 294, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 295, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 297, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 298.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 292, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 293, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 294, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 295. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:296 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:297, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of KAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:298. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 299, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 303. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 299, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 303. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 299, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 303.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 299, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 303. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 299, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 303. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 302, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 304, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 305.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 299, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 300, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 301, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 302. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 303 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 304, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 305. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 306, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 310. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 306, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 310. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 306, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 310.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 306, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 310. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 306, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 310. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 309, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 311, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 312.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 306, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 307, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 308, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 309. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 310 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 311, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 312.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 461, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 481. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 471; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 471. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 313, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 317. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 313, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 317. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 313, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 317.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 313, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 317. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 313, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 317. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 314, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 315, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 316, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 318, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 319.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 313, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 314, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 315, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 316. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 317, and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 318, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 319. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 320, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 324. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 320, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 324. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 320, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 324.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 320, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 324. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 320, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 324. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 323, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 326.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 320, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 321, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 322, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 323. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 324, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 325, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of STS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 326. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 327, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 331. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 327, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 331. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 327, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 331.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 327, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 331. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 327, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 331. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 330, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 332, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 333.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 327, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 328, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 329, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 330. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 331 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 332, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 333. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 334, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 338. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 334, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 338. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 334, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 338.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 334, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 338. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 334, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 338. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 337, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 339, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 340.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 334, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 335, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 336, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 337. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 338, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 339, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 340. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 341, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 345. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 341, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 345. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 341, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 345.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 341, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 345. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 341, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 345. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 344, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 346, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 347.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 341, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 342, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 343, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 344. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 345, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 346, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 347. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 348, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 352. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 348, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 352. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 348, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 352.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 348, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 352. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 348, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 352. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 351, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 353, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTA, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 354.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 348, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 349, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 350, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 351. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 352 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 353, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 354. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 355, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 359. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 355, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 359. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 355, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 359.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 355, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 359. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 355, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 359. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 358, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 360, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 361.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 355, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 356, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 357, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 358. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 359 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 360, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 361. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 362, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 366. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 362, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 366. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 362, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 366.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 362, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 366. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 362, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 366. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 365, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 367, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 368.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 362, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 363, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 364, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 365. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 366, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 367, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 368. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 369, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 373. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 369, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 373. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 369, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 373.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 369, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 373. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 369, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 373. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 372, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 374, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 375.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 369, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 370, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 371, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 372. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 373, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 374, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GTS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 375. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 376, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 380. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 376, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 380. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 376, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 380.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 376, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 380. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 376, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 380. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 379, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 381, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ETS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 382.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 376, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 377, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 378, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 379. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 380 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 381, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of ETS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 382. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 383, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 387. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 383, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 387. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 383, and a variable light chain (VL) region having an amino acid sequence at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 387.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 383, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 387. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 383, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 387. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 386, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 388, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 389.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 383, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 384, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 385, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 386. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 387, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 388, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 389. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 390, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 394. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 390, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 394. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 390, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 394.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 390, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 394. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 390, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 394. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 393, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 395, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 396.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 390, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 391, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 392, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 393. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 394 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 395, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 396.In some embodiments, the antibody comprises a first heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 462, and a second heavy chain (HC) region comprising an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 482. a second heavy chain region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 472; and a light chain (LC) region comprising an amino acid sequence with at least 80% identity (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 472. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 397, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 401. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 397, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 401. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 397, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 401.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 397, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 401. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 397, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 401. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 398, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 399, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 400, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 403.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 397, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 398, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 399, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 400. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 401, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 402, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 403. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 404, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 408. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 404, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 408. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 404, and a variable light chain (VL) region having an amino acid sequence at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 408.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 404, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 408. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 404, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 408. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 405, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 406, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 407, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 409, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 410.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 404, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 405, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 406, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 407. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:408 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:409, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:410. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 411, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 415. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 411, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 415. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 411, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 415.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 411, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 415. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 411, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 415. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 412, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 413, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 414, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 416, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 417.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 411, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 412, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 413, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 414. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 415, and comprising complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 416, CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAF, and CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 417. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 418, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 422. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 418, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 422. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 418, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 422.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 418, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 422. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 418, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 422. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 419, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 420, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 421, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 423, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 424.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 418, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 419, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 420, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 421. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 422, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 423, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 424. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 425, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 429. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 425, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 429. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 425, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 429.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 425, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 429. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 425, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 429. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 428, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 430, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 431.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 425, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 426, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 427, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 428. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 429, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 430, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 431. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 432, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 436. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 432, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 436. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 432, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 436.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 432, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 436. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 432, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 436. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 435, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 437, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 438.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 432, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 433, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 434, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 435. and a variable light chain (VL) region having an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identical to SEQ ID NO: 436, and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 437, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of GAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 438. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 439, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 443. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 439, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 443. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 439, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 443.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 439, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 443. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 439, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 443. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 440, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 441, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 442, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 444, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 445.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 439, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 440, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 441, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 442. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO: 443 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 444, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of AAS, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 445. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 446, and a variable light chain (VL) region having an amino acid sequence at least 80% identical (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 450. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 446, and a variable light chain (VL) region having an amino acid sequence at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 450. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 446, and a variable light chain (VL) region having an amino acid sequence at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NO: 450.In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 446, and a variable light chain (VL) region having an amino acid sequence at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) identical to SEQ ID NO: 450. In some embodiments, the antibody comprises a variable heavy chain (VH) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 446, and a variable light chain (VL) region having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 450. In some embodiments, the antibody comprises a VH comprising therein a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 449, and a VL comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 451, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DNF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 452.In some embodiments, the antibody (a) has an amino acid sequence at least 80% (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) identity to SEQ ID NO: 446, and comprises a complementarity determining region (CDR) H1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 447, a CDR H2 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 448, and a CDR H3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO: 449. and a variable light chain (VL) region having an amino acid sequence at least 80% identical to SEQ ID NO:450 (e.g., at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more), and comprising therein a complementarity determining region (CDR) L1 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:451, a CDR L2 having an amino acid sequence 100% identical to the amino acid sequence of DNF, and a CDR L3 having an amino acid sequence 100% identical to the amino acid sequence of SEQ ID NO:452. In some embodiments, the antibody binds to one or more amino acid residues in the VWF CK domain selected from D2726, R2730, K2735, E2744, D2746, K2757, D2763, and T2789. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: D2726, R2730, D2746, and K2757. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: R2730, K2735, E2744, and D2746. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: K2735, D2746, and K2757. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: R2730, D2746, and K2757.In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: K2735, E2744, D2746, and D2763. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: R2730, K2735, E2744, D2746, K2757, and D2763. In some embodiments, the antibody binds to at least amino acid residue K2735 in the VWF CK domain. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: D2726, K2735, and K2757. In some embodiments, the antibody binds to at least the following amino acid residues in the VWF CK domain: K2735 and D2763. In some embodiments, the modified Fc region increases the plasma half-life of the antibody compared to the plasma half-life of an antibody lacking the Fc region modification. In some embodiments, the modified Fc region increases the plasma half-life of an antibody disclosed herein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or more than 20-fold compared to the plasma half-life of an antibody lacking the Fc region modification. In some embodiments, the modified Fc region increases the plasma half-life of an antibody disclosed herein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 75 ...100%, 150%, 100%, 150%, 100%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 150%, 0%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, 10,000%, or more. In some embodiments, the modified Fc region reduces one or more effector functions of an antibody disclosed herein compared to an effector function of an antibody lacking the Fc region modification.In some embodiments, the one or more effector functions are selected from the group consisting of antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), opsonization, phagocytosis, transcytosis, neutralization of infectivity, inflammation, mucosal immunity, and neonatal immunity. In some embodiments, the modified Fc region reduces one or more effector functions of an antibody disclosed herein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to one or more effector functions of an antibody lacking the Fc region modification. In some embodiments, the modified Fc region reduces one or more effector functions of an antibody disclosed herein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold compared to one or more effector functions of an antibody lacking the Fc region modification. In some embodiments, binding of an antibody disclosed herein to a VWF protein does not alter the function of the VWF protein. In some embodiments, binding of an antibody disclosed herein to VWF (e.g., the VWF CK domain) does not inhibit the binding of the VWF protein to one or more binding partners. In some embodiments, the one or more binding partners are selected from the group consisting of Factor VIII (FVIII), collagen, glycoprotein Ib (gp1b), glycoprotein IIb / IIIa (gpIIb / IIIa), and ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13 (ADAMTS13). In some embodiments, the binding of the antibodies disclosed herein does not inhibit VWF protein from binding to platelet cells. In some embodiments, the accumulation of VWF protein in plasma results in a plasma level of VWF protein that is at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold greater than the plasma level of VWF protein in the absence of the antibody.In some embodiments, the accumulation of VWF protein in plasma is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 1000%, 1100%, 1200%, 1300%, 1400%, 1500%, 1600%, 1700%, 1800%, 1900%, 2100%, 2200%, 2300%, 2400%, 2500%, 3000%, 3500%, 4000%, 4500%, 5000%, 5500%, 6000%, 6500%, 7000%, 7500%, 8000%, 9000%, 10000%, 11000%, 12000%, 13000%, 14000%, 15000%, 16000%, 17000%, 18000%, 19000%, 21000%, 22000%, 23000%, 24000%, 25000%, 26000%, 27000%, 28000%, 29000%, 30000%, 31000%, 32000%, 33000%, 34000%, 35000%, 36000%, 37000%, 38000%, 39000%, 41000 In some embodiments, the binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the VWF protein compared to the plasma half-life of the VWF protein in the absence of the antibody. In some embodiments, the binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the VWF protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold compared to the plasma half-life of the VWF protein in the absence of the antibody. In some embodiments, the binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the VWF protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, compared to the plasma half-life of the VWF protein in the absence of the antibody. %, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, or 10,000% increase. In some embodiments, the binding of an antibody disclosed herein to a VWF protein in plasma results in the accumulation of a VWF protein in plasma compared to the plasma level of the FVIII protein in the absence of the antibody. In some embodiments, the accumulation of the FVIII protein in plasma results in a plasma level of the FVIII protein that is at least 1.3-fold, 1.4-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold greater than the plasma level of the FVIII protein in the absence of the antibody. In some embodiments, the accumulation of FVIII protein in plasma is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 900%, 1000%, 1500%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 1000%, 15 ... In some embodiments, the binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the FVIII protein compared to the plasma half-life of the FVIII protein in the absence of the antibody.In some embodiments, the binding of an antibody disclosed herein to VWF in plasma increases the plasma half-life of the FVIII protein by at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold compared to the plasma half-life of the FVIII protein in the absence of the antibody. In some embodiments, binding of an antibody disclosed herein to VWF in plasma extends the plasma half-life of the FVIII protein by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 700%, 800%, 900%, 1000%, 1100%, 1200%, 1300%, 1400%, 1500%, 1600%, 1700%, 1800%, 1900%, 2100%, 2200%, 2300%, 2400%, 2500%, 2600%, 2700%, 2800%, 3100%, 3200%, 3300%, 3400%, 3500%, 3600%, 3700%, 3800%, 3900%, 4100%, 4200%, 4300%, 4400%, 4500%, 4600%, 4700%, 4800%, 4900%, 5100%, 5200%, 5300%, 5400%, 5500%, 5600%, 5700%, 5800%, 5900%, 6000%, 6100%, 6200%, 6300%, 6400%, 6500%, 6600%, 6700%, 6800%, 6900%, 7000%, 7100%, 7200%, 7300%, 7400%, 7500%, 7600 In some embodiments, the antibodies disclosed herein specifically bind to a VWF homodimer comprising two VWF monomers linked tail-to-tail via a CK domain linkage in a 1:1 stoichiometry. In some embodiments, the antibodies disclosed herein specifically bind to a VWF homodimer comprising two VWF monomers linked tail-to-tail via a CK domain linkage in a 2:1 stoichiometry. In some embodiments, the antibodies disclosed herein have a dissociation constant (K) of less than 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 7 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.5 nM, 0.25 nM, 0.1 nM, 0.075 nM, 0.05 nM, 0.025 nM, 0.01 nM, or less. d) binds to the CK domain of the VWF protein. In some embodiments, the antibodies disclosed herein cross-react with VWF proteins of cynomolgus monkeys (Macaca fascicularis), house mice (Mus musculus), and / or dogs (Canis familiaris). In some embodiments, the antibodies disclosed herein have affinity for VWF proteins of cynomolgus monkeys (Macaca fascicularis), house mice (Mus musculus), and / or dogs (Canis familiaris) that is up to 10-fold (e.g., up to 10-fold, 9-fold, 8-fold, 7-fold, 6-fold, 5-fold, 4-fold, 3-fold, 2-fold, 1.5-fold, or lower) lower than the affinity of the antibody for human VWF proteins. In some embodiments, the antibodies disclosed herein are human, humanized, or chimeric antibodies. In some embodiments, the CK domain is located between amino acid positions 2,723 and 2,813 of SEQ ID NO: 1. In some embodiments, the CK domain is a CK domain of a human VWF protein having at least 85% sequence identity (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to the amino acid sequence of any one of SEQ ID NOs: 5, 6, 486, or 487. In some embodiments, the CK domain has the amino acid sequence of SEQ ID NO: 5. In some embodiments, the CK domain is a CK domain of a non-human primate (NHP) VWF protein having at least 85% sequence identity (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to the amino acid sequence of SEQ ID NO: 6. In some embodiments, the CK domain has the amino acid sequence of SEQ ID NO:6.

[0005] In certain embodiments, disclosed herein are complexes comprising a VWF protein and a monospecific antibody of the foregoing aspects and embodiments. In some embodiments, the complex comprises a VWF monomer. In some embodiments, the complex comprises a VWF dimer. In some embodiments, the complex comprises a VWF multimer. In some embodiments, the multimer is at least 250 kDa (e.g., at least 250 kDa, 500 kDa, 750 kDa, 1000 kDa, 1,250 kDa, 1,500 kDa, 1,750 kDa, 2,000 kDa, 3,000 kDa, 4,000 kDa, 5,000 kDa, 6,000 kDa, 7,000 kDa, 8,000 kDa, 9,000 kDa, 10,000 kDa). Da, 11,000kDa, 12,000kDa, 13,000kDa, 14,000kDa, 15,000kDa, 16,000kDa, 17,000kDa, 18,000kDa, 19,000kDa, 20,000kDa, 21,000kDa, 22,000kDa, 23,000kDa, 24,000kDa, 25,000kDa, or more

[0006] In certain embodiments herein, disclosed are pharmaceutical compositions comprising the monospecific antibody of the foregoing aspects and embodiments and a pharmaceutically acceptable carrier, diluent, or excipient, hi some embodiments, the pharmaceutically acceptable carrier, diluent, or excipient is selected from the group consisting of stabilizers, buffers, surfactants, bulking agents, solvents, tonicity or osmolality adjusters, antioxidants, adjuvants, and antimicrobial agents.

[0007] Certain embodiments disclosed herein are methods for treating a blood disorder characterized by excessive bleeding in a subject in need thereof, the method comprising administering to the subject a monospecific antibody or pharmaceutical composition of any of the foregoing aspects and embodiments. In some embodiments, the blood disorder is selected from the group consisting of von Willebrand disease (VWD), Heydes syndrome, hemophilia A, a platelet function disorder, and a connective tissue disorder. In some embodiments, the VWD is congenital VWD (cVWD) or acquired VWD (aVWD). In some embodiments, the VWD is type 1, type 2A, type 2B, type 2M, type 2N, or type 3. In some embodiments, the compositions disclosed herein treat one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) symptoms of a blood disorder selected from the group consisting of epistaxis, skin bleeding, bleeding from minor wounds, oral bleeding, angiodysplasia, gastrointestinal bleeding, bleeding from tooth extraction, postoperative bleeding, heavy menstrual bleeding, birth bleeding, hematuria, muscle hematoma, joint bleeding, visceral bleeding, and central nervous system (CNS) bleeding. In some embodiments, the compositions or pharmaceutical compositions disclosed herein promote platelet adhesion, activation, and aggregation in a subject.

[0008] In certain embodiments, disclosed herein are methods for accumulating VWF protein in the plasma of a subject in need thereof, the method comprising administering to the subject a composition comprising the monospecific antibody of any of the foregoing aspects and embodiments.

[0009] In certain embodiments, disclosed herein are methods for accumulating FVIII protein in the plasma of a subject in need thereof, the method comprising administering to the subject a composition comprising the monospecific antibody of any of the foregoing aspects and embodiments.

[0010] In certain embodiments herein, a method for increasing the plasma half-life of a VWF protein in a subject in need thereof is disclosed, the method comprising administering to the subject a composition comprising the monospecific antibody of any of the foregoing aspects and embodiments.

[0011] In certain embodiments herein, a pharmaceutical composition is disclosed comprising a monospecific antibody disclosed herein and a pharmaceutically acceptable carrier, diluent, or excipient. In some embodiments, the pharmaceutically acceptable carrier, diluent, or excipient is selected from the group consisting of stabilizers, buffers, surfactants, bulking agents, solvents, tonicity or osmolality adjusting agents, antioxidants, adjuvants, and antimicrobial agents. In some embodiments, the pharmaceutical composition disclosed herein is administered in combination with one or more (e.g., 1, 2, 3, 4, 5, or more) additional therapeutic measures. In some embodiments, the one or more additional therapeutic measures are one or more therapeutic agents. In some embodiments, the one or more additional therapeutic agents are selected from the group consisting of desmopressin (DDAVP), tranexamic acid (TXA), thalidomide, tamoxifen, ocreotide, concentrates of plasma-derived VWF protein, concentrates of VWF protein in a complex with FVIII protein (VWF; FVIII; e.g., Humate P and Wilate), concentrates of recombinant VWF protein (e.g., Vonicog alfa), concentrates of FVIII protein (e.g., Alphanate and Koate-HP), hormonal treatments (e.g., oral contraceptive pills, such as estrogen-containing contraceptives, and intrauterine devices). In some embodiments, the one or more additional therapeutic agents are surgery. In some embodiments, the one or more additional therapeutic agents are blood transfusions. In some embodiments, the one or more additional therapeutic agents are platelet transfusions. In some embodiments, the one or more additional therapeutic agents are ablation. In some embodiments, the one or more additional therapeutic agents are gene therapy. In some embodiments, the gene therapy is FVIII gene therapy.For example, the antibody or composition of the present disclosure may be administered in combination with FVIII gene therapy to extend the half-life of FVIII in the subject's plasma and / or promote the accumulation of FVIII.In some embodiments, the antibody or composition of the present disclosure is administered to patients for whom FVIII gene therapy alone is insufficient to achieve a therapeutically effective level of FVIII in plasma.In some embodiments, the antibody or composition of the present disclosure achieves a therapeutically effective level of FVIII in plasma. In some embodiments, one or more additional therapeutic agents are administered to the subject before, simultaneously with, or after administration of the composition or pharmaceutical composition. In some embodiments, one or more additional therapeutic agents are administered to the subject before administration of the composition or pharmaceutical composition. In some embodiments, one or more additional therapeutic agents are administered to the subject simultaneously with administration of the composition or pharmaceutical composition. In some embodiments, one or more additional therapeutic agents are administered to the subject after administration of the composition or pharmaceutical composition.

[0012] In certain embodiments herein, a kit is disclosed comprising the monospecific antibody or pharmaceutical composition of the aforementioned aspects and embodiments and a package insert instructing a user of the kit to carry out the method of the aforementioned aspects and embodiments.

[0013] In certain embodiments herein, the monospecific antibodies and pharmaceutical compositions of the preceding embodiments are disclosed for use as medicaments. In some embodiments, the monospecific antibodies or pharmaceutical compositions of the preceding embodiments are for use in treating a blood disorder characterized by excessive bleeding.

[0014] In certain embodiments herein, disclosed is the monospecific antibody or pharmaceutical composition of the preceding embodiments for use in treating a blood disorder characterized by excessive bleeding.

[0015] In some embodiments of the foregoing aspects, the blood disorder characterized by excessive bleeding is selected from the group consisting of VWD, Heydes syndrome, hemophilia A, platelet function disorders, and connective tissue disorders. In some embodiments, the VWD is cVWD or aVWD. In some embodiments, the VWD is type 1, type 2A, type 2B, type 2M, type 2N, or type 3.

[0016] definition Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. Generally, the immunology, oncology, cell and tissue culture, molecular biology, and protein and oligonucleotide or polynucleotide chemistry and hybridization described herein, and the nomenclature utilized in conjunction with these techniques, are well known and commonly used in the art. It should be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not intended to limit all claimed subject matter. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.

[0017] As used herein, the singular forms "a," "and," and "the" include the plural forms unless the context clearly dictates otherwise. Thus, for example, reference to "an antibody" includes a plurality of antibodies, and in some embodiments reference to "an antibody" includes a plurality of antibodies.

[0018] As used herein, all numerical values ​​or ranges of values ​​include whole integers within or encompassing such ranges, and fractions of values ​​or integers within or encompassing such ranges, unless the context clearly dictates otherwise. Thus, for example, a reference to a range of 90-100% includes 91%, 92%, 93%, 94%, 95%, 95%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc. In another example, a reference to a range of 1 to 5,000 times includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 times, etc., as well as 1.1, 1.2, 1.3, 1.4, 1.5 times, etc., 2.1, 2.2, 2.3, 2.4, 2.5 times, etc.

[0019] As used herein, a number preceded by "about" refers to a range that includes the number and extends from 10% below that number to 10% above that number. A range preceded by "about" refers to 10% below the lower limit of the range and extends to 10% above the upper limit of the range.

[0020] As used herein, the term "accumulation" refers to an increase in the level (e.g., concentration) of a particular protein, such as VWF or FVIII, in the blood compartment (e.g., plasma) of a subject after administration of an antibody of the present disclosure or a composition containing the same (e.g., a pharmaceutical composition) to the subject. Various factors may affect the rate of accumulation of a protein in the blood compartment of a subject, including, but not limited to, the half-life of the target protein and / or antibody in the blood compartment, the rate of sequestration of the protein by other tissues, and clearance of the protein from the body. According to the present disclosure, accumulation of a target protein (e.g., VWF or FVIII) may result in a plasma level of the protein that is at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, or 20-fold greater than the plasma level of the protein in the absence of the antibody. Alternatively, accumulation of the target protein is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 550%, 600%, 650%, 700%, 750%, 800%, 850%, 900%, 1000%, 150 ... %, 950%, 1,000%, 1,500%, 2,000%, 2,500%, 3,000%, 3,500%, 4,000%, 4,500%, 5,000%, 5,500%, 6,000%, 6,500%, 7,000%, 7,500%, 8,000%, 8,500%, 9,000%, 9,500%, 10,000%, or more. In some embodiments, the accumulation of a protein (e.g., VWF) results directly from the specific binding of an antibody of the present disclosure to the protein. In some embodiments, the accumulation of a protein (e.g., FVIII) results indirectly from the binding of a protein (e.g., FVIII) to another protein (e.g., VWF) bound by an antibody of the present disclosure.

[0021] As used herein, "antibody" refers to a naturally occurring or non-naturally occurring protein that binds to an antigen. Antibodies often contain variable domains and constant regions in each of their heavy and light chains. Thus, most antibodies contain a heavy chain variable domain (V) that together form the portion of the antibody that binds the antigen, sometimes referred to as the "antigen receptor." H ) and the light chain variable domain (V L Within each variable domain there are three complementarity determining regions (CDRs), V H and V L The antibody forms a loop within the antibody molecule and contacts the surface of the antigen. "Antibody" includes, but is not limited to, monoclonal antibodies, monospecific antibodies, univalent antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, chimeric antibodies, synthetic antibodies, recombinant antibodies, hybrid antibodies, mutated antibodies, grafted antibodies, antibody fragments, and in vitro generated antibodies that have antigen-binding activity. The term also includes antibody conjugates that have advantageous properties compared to non-conjugated antibodies (e.g., antibodies conjugated to half-life extending moieties, e.g., fatty acids).

[0022] As used herein, the terms "complementarity-determining region," "CDR," and "hypervariable region" refer to the portions of the variable domain in an antibody that determine the specificity with which the antibody binds to its specific antigen. A variable region of an antibody polypeptide typically contains three CDRs, usually designated CDR1, CDR2, and CDR3. More specifically, a heavy chain variable region may contain CDRs designated H1, H2, and H3, and a light chain variable region may contain CDRs L1, L2, and L3. Many methods may be used to define CDRs. Currently, various numbering schemes are used in the art, with various definitions of the length and position of CDRs. For example, the IMGT numbering scheme is a standard numbering system based on the alignment of sequences from a complete reference gene database containing the entire immunoglobulin superfamily. The Kabat numbering scheme is based on sequence alignment and uses the "variability parameter" of a given amino acid position (the number of different amino acids at a given position divided by the frequency of the majority of amino acids occurring at that position) to predict CDRs. The Chothia numbering scheme, on the other hand, is a structure-based numbering scheme in which antibody crystal structures are aligned to define loop structures as CDRs. The Martin numbering scheme focuses on the structural alignment of different framework regions of variable length. The Honneger numbering scheme (AHo's) is based on the structural alignment of the 3D structures of variable regions and uses structurally conserved Cα positions to estimate framework and CDR lengths. Those skilled in the art will note that the definition of CDRs varies depending on the method used. Therefore, the CDR sequences of a given heavy or light chain variable region may vary depending on the numbering system used. All methods of defining CDRs are contemplated for the sequences disclosed herein. Unless otherwise specified, the CDRs disclosed herein are defined according to the IMGT numbering system.

[0023] The terms "antigen-binding portion of an antibody," "antigen-binding fragment," "antigen-binding domain," and "antibody fragment" are used interchangeably herein to refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. Non-limiting examples of antibody fragments encompassed within such terms include, for example, Fab fragments and V L , V H , C L , and C H1 Examples of antibodies include, but are not limited to, monovalent fragments consisting of a domain, and also include "one-arm" antibodies comprising a single heavy chain, a truncated heavy chain lacking the Fab region, and a single light chain.

[0024] As used herein, the phrase "blood disorder characterized by excessive bleeding" refers to one or more disorders in a subject (e.g., a human) that render the subject susceptible to bleeding (e.g., a bleeding diathesis). Such disorders, in some embodiments, result from conditions associated with atypical and slow blood clotting. "Blood disorders characterized by excessive bleeding" can be inherited or acquired. Platelet activation, adhesion, and / or aggregation (e.g., primary hemostasis) are impaired in some embodiments in subjects with the aforementioned disorders. In some embodiments, the function or expression of blood proteins that mediate or promote the production of insoluble cross-linked fibrin proteins during blood clotting (e.g., secondary hemostasis) is impaired in subjects with the disorder. Non-limiting examples of blood disorders characterized by excessive bleeding include von Willebrand disease (VWD), hemophilia A, platelet function disorders, and connective tissue disorders. In some embodiments, VWD is congenital VWD (cVWD) or acquired VWD (aVWD). In some embodiments, the aVWD comprises Heydes syndrome. In some embodiments, the VWD is type 1, type 2A, type 2B, type 2M, type 2N, or type 3.

[0025] As used herein, the term "altered function" when referring to a VWF protein means that the inherent function of the VWF protein is increased or decreased by a substantial amount (e.g., 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, "VWF" refers to an increase or decrease in the ability of VWF to bind to other proteins, including the binding partners described herein. VWF lacks enzymatic activity and its function is associated with binding and stabilizing other proteins involved in blood coagulation. Therefore, the function of VWF is primarily to bind to other proteins, including the binding partners described herein. Therefore, an "altered function" of VWF corresponds to an increase or decrease in the ability of VWF to bind to other proteins, such as its binding partners.

[0026] As used herein, the term "complex" refers to a molecular entity formed by two or more physically associated molecules (e.g., proteins), such as, for example, a VWF protein and an antibody described herein. The two or more molecules are associated, in some embodiments, by any physical means, including covalent bonds, ionic bonds, hydrogen bonds, and van der Waals forces. In some embodiments, the physical association between the two or more molecules is reversible. In some embodiments, the physical association between the two or more molecules is irreversible.

[0027] As used herein, the term "effective amount" refers to an amount of an antibody described herein or its antigen-binding partner that is sufficient to induce a disclosed effect when administered to a subject, e.g., to achieve treatment (e.g., accumulation of VWF and / or FVIII protein in plasma), prognosis, or diagnosis of a disease (e.g., a blood disorder characterized by excessive bleeding) as described herein. Therapeutically effective amounts of antibodies provided herein will vary depending on the relative activities of the antibodies and combinations of the disclosure (e.g., in treating, reducing, or ameliorating a disease or disorder described herein) when used alone or in combination, as well as depending on the subject and disease state being treated, the subject's weight and age, the severity of the disease state, the method of administration, etc., and in some cases will be readily determined by one of ordinary skill in the art.

[0028] As used herein, the term "monospecific" refers to an antibody that exhibits preferential affinity for one particular epitope (e.g., an epitope contained in the CK domain of a VWF protein, such as a human, NHP, mouse, or canine VWF protein).

[0029] As used herein, the term "monovalent" refers to the property of an antibody or antigen-binding fragment thereof having one antigen-binding site for a target epitope of a particular protein. For example, a monovalent antibody of the present disclosure binds to an epitope of the VWF protein (e.g., an epitope in the CK domain) through a single antigen-binding site. Within the context of the present disclosure, a monovalent antibody is, in some embodiments, a single-arm antibody (e.g., one having a heavy chain, a truncated heavy chain lacking the Fab region, and a single light chain).

[0030] As used herein, the term "one-armed antibody" or "single-armed antibody" refers to a type of monovalent antibody fragment that contains an antibody heavy chain, a truncated heavy chain lacking the Fab region, and a single light chain.

[0031] "Percent identity" and "% identity" refer to the degree to which two sequences (nucleotides or amino acids) have the same residues at the same positions in an alignment. For example, "an amino acid sequence is X% identical to SEQ ID NO: Y" refers to the % identity of an amino acid sequence to SEQ ID NO: Y, and states that X% of the residues in the amino acid sequence are identical to the residues in the sequence disclosed in SEQ ID NO: Y. Generally, computer programs are used for such calculations. Exemplary programs for comparing and aligning pairwise sequences include ALIGN (Myers and Miller, Comput Appl Biosci. 1988 March;4(1):11-7), FASTA (Pearson and Lipman, Proc Natl Acad Sci USA. 1988 April;85(8):2444-8; Pearson, Methods Enzymol. 1990;183:63-98), gapped BLAST (Altschul et al., Nucleic Acids Res 1997 September 1;25(17):3389-40), BLASTP, BLASTN, or GCG (Devereux et al., Nucleic Acids Res. 1984 January 11;12(1 Pt 1):387-95).

[0032] The term "polypeptide" refers to a chain of amino acids (e.g., naturally occurring or non-naturally occurring amino acids). In some embodiments, a polypeptide comprises naturally occurring amino acids. In some embodiments, a polypeptide comprises non-naturally occurring amino acids (e.g., cystine, desmosine, isodesmosine, hydroxyproline, hydroxylysine, gamma-carboxyglutamate, phosphoserine, phosphothreonine, phosphotyrosine, N-acetyllysine, methyllysine, inositol, L-homoalanine, L-2-aminobutyric acid, L-azidohomoalanine, β-phenylalanine, norleucine, 3-fluorotyrosine, 4-fluorophenylalanine, L-aminobutyric acid ... Polypeptides include, but are not limited to, 3,4-dihydroxyphenylalanine, pNCSF, L-(7-hydroxycoumarin-4-yl)ethylglycine, 2,3-dihydroxypropylcysteine, arylglycine, PrDiAzK, (S)-N-(2-benzoylphenyl)-1-(2-flurobenzyl)-pyrrolidine-2-carboxamide, 4-phenanthracen-9-yl-l-phenylalanine, BN tryptophan analog, p-acetylphenylalanine, and L-azidohomoalanine. Polypeptides are not limited to a specific length of the product (e.g., a polypeptide can contain at least two amino acids linked together by a peptide bond). Peptides, oligopeptides, and proteins are included in the definition of polypeptide, and such terms are used interchangeably herein unless otherwise specified. The term also encompasses peptide chains with post-expression modifications, such as glycosylation, acetylation, phosphorylation, and other modifications known in the art, both naturally occurring and non-naturally occurring. In some embodiments, the polypeptide is a whole protein or a fragment thereof.

[0033] The terms "preferentially binds" or "specifically binds" mean that an antibody or fragment thereof binds to an epitope with greater affinity than it binds to an unrelated amino acid sequence, and, if cross-reactive with other polypeptides containing the epitope, is non-toxic at levels formulated for administration to humans. In some embodiments, such affinity is at least 1.5-fold, 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, 10-fold, at least 20-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 58-fold, at least 70-fold, at least 80-fold, at least 90-fold, at least 94-fold, or at least 100-fold greater than the affinity of the antibody o...

Claims

1. A monospecific antibody comprising (i) an antigen-binding site that specifically binds to an epitope of von Willebrand factor (VWF) protein located in a cysteine ​​knot (CK) domain, and (ii) a fragment crystallizable (Fc) region, wherein binding of the monospecific antibody to the epitope of the VWF protein in plasma results in accumulation of the VWF protein in plasma compared to the plasma level of the VWF protein in the absence of the monospecific antibody.

2. The binding of the monospecific antibody to the epitope of the VWF protein is (i) increasing the plasma half-life of the VWF protein in plasma compared to the plasma half-life of the VWF protein in the absence of the monospecific antibody; (ii) increasing the plasma half-life of the Factor VIII (FVIII) protein in plasma compared to the plasma half-life of the FVIII protein in the absence of the monospecific antibody; (iii) resulting in an accumulation of Factor VIII (FVIII) protein in plasma compared to the plasma level of FVIII protein in the absence of the monospecific antibody; (iv) does not alter the function of the VWF protein, and / or (v) The monospecific antibody of claim 1, which does not inhibit the binding of the VWF protein to one or more binding partners.

3. The monospecific antibody of claim 1, which binds to one or more amino acid residues of the VWF CK domain, including D2726, R2730, K2735, E2744, D2746, K2757, D2763, T2789, or any combination thereof.

4. The VWF CK domain contains at least the following amino acid residues: (a) D2726, R2730, D2746, and K2757; (b) R2730, K2735, E2744, and D2746; (c) K2735, D2746, and K2757; (d) R2730, D2746, and K2757; (e) K2735, E2744, D2746, and D2763; (f) R2730, K2735, E2744, D2746, K2757, and D2763; (g) K2735, (h) D2726, K2735, and K2757, or (i) K2735 and D2763 The monospecific antibody of claim 3, which binds to

5. A monospecific antibody as described in claim 1, wherein the epitope of the VWF protein is located within a VWF homodimer comprising two VWF monomers whose tails are linked together via a CK domain bond in a 1:1 stoichiometry, or wherein the epitope of the VWF protein is located within a VWF homodimer comprising two VWF monomers whose tails are linked together via a CK domain bond in a 2:1 stoichiometry.

6. A monospecific antibody described in claim 1, wherein the CK domain has the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO:

6.

7. A polypeptide comprising a variable heavy domain (VH) and a variable light domain (VL), (a) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 40, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 44; (b) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 12, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 16; (c) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 19, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 23; (d) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 33, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 37; (e) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 89, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 93; (f) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 26, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 30; (g) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 47, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 51; (h) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 54, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 58; (i) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 61, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 65; (j) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 68, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 72; (k) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 75, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 79; (l) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 82, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 86; (m) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 96, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 100; (n) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 103, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 107; (o) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 110, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 114; (p) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 117, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 121; (q) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 124, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 128; (r) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 131, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 135; (s) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 138, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 142; (t) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 145, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 149; (u) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 152, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 156; (v) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 159, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 163; (w) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 166, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 170; (x) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 173, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 177; (y) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 180, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 184; (z) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 187, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 191; (aa) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 194, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 198; (bb) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 201, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 205; (cc) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 208, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 212; (dd) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 215, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 219; (ee) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 222, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 226; (ff) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 229, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 233; (gg) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 236, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 240; (hh) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 243, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 247; (ii) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 250, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 254; (jj) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 257, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 261; (kk) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 264, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 268; (ll) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 271, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 275; (mm) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 278, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 282; (nn) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 285, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 289; (oo) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 292 and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 296; (pp) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 299 and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 303; (qq) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 306, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 310; (rr) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 313 and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 317; (ss) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 320, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 324; (tt) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 327, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 331; (uu) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 334, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 338; (vv) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 341, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 345; (ww) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 348, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 352; (xx) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 355, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 359; (yy) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 362, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 366; (zz) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 369, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 373; (aaa) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 376, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 380; (bbb) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 383, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 387; (ccc) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 390, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 394; (ddd) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 397, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 401; (eee) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 404, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 408; (fff) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 411, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 415; (ggg) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 418, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 422; (hhh) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 425, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 429; (iii) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 432, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 436; (jjj) the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 439, and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 443; or (kkk) The monospecific antibody of claim 1, wherein the VH comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 446 and the VL comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO:

450.

8. A variable heavy chain domain (VH) comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3), and a variable light chain domain (VL) comprising three light chain CDRs (CDR-L1, CDR-L2, and CDR-L3), (a) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 41, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 42, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 43, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 45, the CDR-L2 comprises the amino acid sequence of GSS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 46; (b) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 13, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 14, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 15, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 17, the CDR-L2 comprises the amino acid sequence of KAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 18; (c) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 20, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 21, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 22, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 24, the CDR-L2 comprises the amino acid sequence of AAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 25; (d) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 34, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 35, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 36, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 38, the CDR-L2 comprises the amino acid sequence of DAT, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 39; (e) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 90, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 91, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 92, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 94, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 95; (f) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 27, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 28, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 29, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 31, the CDR-L2 comprises the amino acid sequence of ESS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 32; (g) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 48, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 49, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 50, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 52, the CDR-L2 comprises the amino acid sequence of DAT, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 53; (h) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 55, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 56, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 57, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 59, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 60; (i) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 62, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 63, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 64, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 66, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 67; (j) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 69, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 70, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 71, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 73, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 74; (k) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 76, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 77, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 78, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 80, the CDR-L2 comprises the amino acid sequence of HAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 81; (l) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 83, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 84, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 85, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 87, the CDR-L2 comprises the amino acid sequence of DAT, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 88; (m) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 97, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 98, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 99, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 101, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 102; (n) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 104, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 105, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 106, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 108, the CDR-L2 comprises the amino acid sequence of DIS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 109; (o) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 111, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 112, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 113, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 115, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 116; (p) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 118, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 119, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 120, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 122, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 123; (q) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 125, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 126, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 127, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 129, the CDR-L2 comprises the amino acid sequence of EAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 130; (r) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 132, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 133, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 134, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 136, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 137; (s) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 139, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 140, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 141, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 143, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 144; (t) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 146, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 147, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 148, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 150, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 151; (u) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 153, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 154, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 155, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 157, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 158; (v) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 160, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 161, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 162, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 164, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 165; (w) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 167, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 168, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 169, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 171, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 172; (x) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 174, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 175, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 176, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 178, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 179; (y) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 181, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 182, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 183, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 185, the CDR-L2 comprises the amino acid sequence of DVS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 186; (z) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 188, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 189, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 190, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 192, the CDR-L2 comprises the amino acid sequence of DAT, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 193; (aa) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 195, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 196, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 197, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 199, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 200; (bb) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 202, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 203, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 204, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 206, the CDR-L2 comprises the amino acid sequence of GVD, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 207; (cc) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 209, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 210, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 211, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 213, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 214; (dd) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 216, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 217, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 218, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 220, the CDR-L2 comprises the amino acid sequence of GAT, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 221; (ee) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 223, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 224, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 225, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 227, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 228; (ff) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 230, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 231, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 232, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 234, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 235; (gg) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 237, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 238, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 239, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 241, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 242; (hh) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 244, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 245, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 246, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 248, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 249; (ii) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 251, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 252, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 253, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 255, the CDR-L2 comprises the amino acid sequence of GAT, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 256; (jj) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 258, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 259, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 260, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 262, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 263; (kk) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 265, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 266, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 267, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 269, the CDR-L2 comprises the amino acid sequence of DAV, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 270; (ll) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 272, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 273, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 274, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 276, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 277; (mm) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 279, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 280, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 281, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 283, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 284; (nn) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 286, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 287, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 288, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 290, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 291; (oo) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 293, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 294, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 295, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 297, the CDR-L2 comprises the amino acid sequence of KAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 298; (pp) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 300, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 301, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 302, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 304, the CDR-L2 comprises the amino acid sequence of AAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 305; (qq) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 307, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 308, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 309, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 311, the CDR-L2 comprises the amino acid sequence of DTS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 312; (rr) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 314, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 315, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 316, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 318, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 319; (ss) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 321, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 322, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 323, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 325, the CDR-L2 comprises the amino acid sequence of STS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 326; (tt) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 328, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 329, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 330, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 332, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 333; (uu) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 335, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 336, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 337, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 339, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 340; (vv) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 342, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 343, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 344, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 346, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 347; (ww) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 349, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 350, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 351, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 353, the CDR-L2 comprises the amino acid sequence of DTS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 354; (xx) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 356, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 357, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 358, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 360, the CDR-L2 comprises the amino acid sequence of AAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 361; (yy) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 363, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 364, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 365, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 367, the CDR-L2 comprises the amino acid sequence of AAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 368; (zz) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 370, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 371, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 372, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 374, the CDR-L2 comprises the amino acid sequence of GTS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 375; (aaa) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 377, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 378, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 379, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 381, the CDR-L2 comprises the amino acid sequence of ETS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 382; (bbb) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 384, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 385, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 386, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 388, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 389; (ccc) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 391, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 392, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 393, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 395, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 396; (ddd) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 398, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 399, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 400, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 402, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 403; (eee) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 405, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 406, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 407, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 409, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 410; (fff) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 412, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 413, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 414, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 416, the CDR-L2 comprises the amino acid sequence of DAF, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 417; (ggg) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 419, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 420, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 421, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 423, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 424; (hhh) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 426, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 427, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 428, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 430, the CDR-L2 comprises the amino acid sequence of DAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 431; (iii) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 433, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 434, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 435, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 437, the CDR-L2 comprises the amino acid sequence of GAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 438; (jjj) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 440, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 441, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 442, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 444, the CDR-L2 comprises the amino acid sequence of AAS, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 445, or (kkk) The monospecific antibody of claim 1, wherein the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 447, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 448, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 449, the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 451, the CDR-L2 comprises the amino acid sequence of DNF, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO:

452.

9. The monospecific antibody of claim 1, wherein the Fc region is a modified Fc region.

10. The modified Fc region is selected from the group consisting of R435H mutation, N434A mutation, T252L / T253S / T254F mutation, E294delta / T307P / N434Y mutation, T256N / A378V / S383N / N434Y mutation, E294delta mutation, M252Y / S254T / T256E mutation, M428L / N434S mutation, T307A / E380A / N434A mutation, T250Q / M428L mutation, T250Q / M428F mutation, T250E / M428F mutation, T250E / M428L mutation, T256D / Q311V / A378V mutation, T256D / H286D / T3 07R / Q311V / A378V mutation, H285N / T307Q / N315D mutation, T307Q / Q311V / A378V mutation, H285D / T307Q / A378V mutation, L234F / L235E / P331S mutation, L234F / L235Q / K322Q mutation, L234F / L235Q / P331G mutation, L234F / L235A / K322Q mutation, S228P / F234A / L235A / G237A / P238S mutation, L234A / L235E / G237A / A330S / P331S mutation, F243A / V264A mutation, S228P / L235E / P329G mutation, M252Y / M428L mutation, D259I / V308F mutation, T307Q / N434S mutation, M428L / V308F mutation, Q311V / N434S mutation, H433K / N434F mutation, E258F / V427T mutation, K288E / H435K mutation, F234A / L235A mutation, F234A / L235A / S228P mutation, L234A / L235A / P329G mutation, F234A / L235A / P329G mutation, P329G mutation, F234 mutation, S228P mutation, delta-K447 mutation, L235A mutation, L235E mutation, V308 P mutation, V308W mutation, V308Y mutation, V308F mutation, N434S mutation, T307 mutation, Q312A mutation, K322A mutation, P329A mutation, P331A mutation, P238A mutation, D265A mutation, D269A mutation, D270A mutation, N297A mutation, A327Q mutation, P329A mutation, S239A mutation, E294A mutation, Q295A mutation, V303A mutation, A330R mutation, T299A mutation, F234A mutation, T366W mutation, T366S mutation, L368A mutation, Y407V mutation, F405L mutation, K409R mutation, F405L / R409K mutation,10. The monospecific antibody of claim 9, comprising one or more mutations relative to the wild-type Fc region, including:

11. The monospecific antibody of claim 1, which is a human IgG4 antibody comprising a first heavy chain and a second heavy chain. Claim 12: (i) (a) the first heavy chain comprises S228P / T366W / F234A / L235A / delta-K447 mutations and the second heavy chain comprises S228P / T366S / L368A / Y407V / F234A / L235A / delta-K447 mutations, or (b) the first heavy chain comprises S228P / T366W / delta-K447 mutations and the second heavy chain comprises S228P / T366S / L368A / Y407V / delta-K447 mutations; and / or 12. The monospecific antibody of claim 11, wherein (ii) the first heavy chain and the second heavy chain further comprise M252Y / S254T / T256E mutations.

13. A complex comprising a VWF protein and a monospecific antibody described in claim 1.

14. A pharmaceutical composition comprising the monospecific antibody of any one of claims 1 to 12 and a pharmaceutically acceptable carrier, diluent, or excipient.

15. Use of the pharmaceutical composition of claim 14 in the manufacture of a medicament for treating a blood disorder characterized by excessive bleeding in a subject in need of such treatment.

16. The use of claim 15, wherein the blood disorder comprises von Willebrand disease (VWD), Heydes syndrome, hemophilia A, a platelet dysfunction disorder, a connective tissue disorder, or any combination thereof.

17. The use of claim 16, wherein the VWD is congenital VWD (cVWD), acquired VWD (aVWD), or VWD type 1, type 2A, type 2B, type 2M, type 2N, or type 3.

18. A pharmaceutical composition comprising a monospecific antibody according to any one of claims 1 to 12 and a pharmaceutically acceptable carrier, diluent, or excipient for use in treating a blood disorder characterized by excessive bleeding in a subject in need thereof.

19. The pharmaceutical composition of claim 18, wherein the blood disorder comprises von Willebrand disease (VWD), Heydes syndrome, hemophilia A, a platelet dysfunction disorder, a connective tissue disorder, or any combination thereof.

20. The pharmaceutical composition of claim 19, wherein the VWD is congenital VWD (cVWD), acquired VWD (aVWD), or VWD: type 1, type 2A, type 2B, type 2M, type 2N, or type 3.

Images